KR20240004273A - 당뇨병을 위한 hb-egf 유전자 요법 - Google Patents

당뇨병을 위한 hb-egf 유전자 요법 Download PDF

Info

Publication number
KR20240004273A
KR20240004273A KR1020237033566A KR20237033566A KR20240004273A KR 20240004273 A KR20240004273 A KR 20240004273A KR 1020237033566 A KR1020237033566 A KR 1020237033566A KR 20237033566 A KR20237033566 A KR 20237033566A KR 20240004273 A KR20240004273 A KR 20240004273A
Authority
KR
South Korea
Prior art keywords
egf
leu
gly
lys
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237033566A
Other languages
English (en)
Korean (ko)
Inventor
켄이치로 코사이
에리코 마츠다
Original Assignee
가고시마 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가고시마 유니버시티 filed Critical 가고시마 유니버시티
Publication of KR20240004273A publication Critical patent/KR20240004273A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237033566A 2021-03-03 2022-03-02 당뇨병을 위한 hb-egf 유전자 요법 Pending KR20240004273A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021033714 2021-03-03
JPJP-P-2021-033714 2021-03-03
JP2021145796 2021-09-07
JPJP-P-2021-145796 2021-09-07
PCT/JP2022/008898 WO2022186282A1 (ja) 2021-03-03 2022-03-02 糖尿病に対するhb-egf遺伝子治療

Publications (1)

Publication Number Publication Date
KR20240004273A true KR20240004273A (ko) 2024-01-11

Family

ID=83154306

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033566A Pending KR20240004273A (ko) 2021-03-03 2022-03-02 당뇨병을 위한 hb-egf 유전자 요법

Country Status (12)

Country Link
US (1) US20240173381A1 (cg-RX-API-DMAC7.html)
EP (1) EP4302785A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022186282A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240004273A (cg-RX-API-DMAC7.html)
AU (1) AU2022230492A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023017808A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212726A1 (cg-RX-API-DMAC7.html)
IL (1) IL305627A (cg-RX-API-DMAC7.html)
MX (1) MX2023010315A (cg-RX-API-DMAC7.html)
PH (1) PH12023552425A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022186282A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309227B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
JP7868817B2 (ja) * 2024-04-02 2026-06-02 国立大学法人 鹿児島大学 糖尿病に対するsHB-EGF強化治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4839476B2 (ja) * 2005-09-28 2011-12-21 国立大学法人 鹿児島大学 ヘパリン結合性上皮増殖因子様増殖因子の新規医薬用途
JP2007223939A (ja) * 2006-02-22 2007-09-06 Kobe Univ エネルギー代謝促進因子としてのhb−egfの使用
JP5174022B2 (ja) * 2007-07-20 2013-04-03 学校法人 埼玉医科大学 膵臓β細胞増加促進剤及び膵臓β細胞増加促進組成物
JP6711495B1 (ja) 2019-05-27 2020-06-17 株式会社ナイスリー 車両用盗難防止装置
JP2021033714A (ja) 2019-08-26 2021-03-01 東芝テック株式会社 商品販売データ処理装置及びプログラム
JP7040807B2 (ja) 2020-03-17 2022-03-23 株式会社オリンピア 遊技機

Also Published As

Publication number Publication date
WO2022186282A1 (ja) 2022-09-09
MX2023010315A (es) 2023-11-24
ZA202309227B (en) 2024-06-26
PH12023552425A1 (en) 2024-02-19
CA3212726A1 (en) 2022-09-09
US20240173381A1 (en) 2024-05-30
AU2022230492A1 (en) 2023-10-19
JPWO2022186282A1 (cg-RX-API-DMAC7.html) 2022-09-09
IL305627A (en) 2023-11-01
EP4302785A1 (en) 2024-01-10
BR112023017808A2 (pt) 2023-09-26
EP4302785A4 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
EP3268024B1 (en) Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
US20240173381A1 (en) Hb-egf gene therapy for diabetes
US8361960B2 (en) Periostin-induced pancreatic regeneration
EP3741845A1 (en) Recombinant vaccinia virus and pharmaceutical composition comprising same
CN119487057A (zh) 截短蛋白及其用途
RU2853169C2 (ru) Генотерапия с использованием hb-egf для лечения диабета
EP3400024B1 (en) A combination therapy using reic/dkk-3 gene and a checkpoint inhibitor
HK40103669A (en) Hb-egf gene therapy for diabetes
JP7857666B2 (ja) 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療
CN117279670A (zh) 用于糖尿病的hb-egf基因治疗
WO2020091066A1 (en) A combination therapy for treatment of thoracic cancer using Ad-REIC/Dkk-3 and a checkpoint inhibitor
HK40095489A (en) Low-dose hepatocyte growth factor gene therapy for diabetes
Mahato Gene expression and silencing for improved islet transplantation
CN116685340A (zh) 针对糖尿病的低剂量的肝细胞生长因子基因治疗
US9433659B2 (en) Enhanced glycemic control using Ad36E4orf1 and AKT1 inhibitor
Gur et al. Destination Penis? Gene therapy as a possible treatment for Erectile Dysfunction
EP2307542A1 (en) Method for treating or preventing radiation damage by in vivo gene therapy
US20020031493A1 (en) Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
WO2022020548A2 (en) Variant txnip compositions and methods of use thereof for the treatment of degenerative ocular diseases
WO2025211357A1 (ja) 糖尿病に対するsHB-EGF強化治療
JP2006524712A (ja) カテプシンの阻害のための方法および組成物
WO2022170919A1 (zh) 一种重组溶瘤腺病毒及其应用
HK40104471A (en) Expression cassettes for target genes and their applications
WO2025019820A1 (en) All in one vectors for the treatment of facioscapulohumeral muscular dystrophy
WO2013117776A1 (es) Enzimas glucocinasas con actividad aumentada y su uso en el tratamiento y/o prevención de la diabetes mellitus

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230927

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250124

Comment text: Request for Examination of Application